Citi Reiterates Buy, $49 PT on Gilead

In a note out today, Citigroup reiterated a buy rating and $49 price target on Gilead Sciences

GILD

Start Futures Trading Fast — with a $200 Bonus

Join Plus500 today and get up to $200 to start trading real futures. Practice with free paper trading, then jump into live markets with lightning-fast execution, low commissions, and full regulatory protection.

while noting “Gilead is slated to post an 22% EPS CAGR from 2012-'15 due to its premier HIV franchise and hepC sales. This puts Gilead to be one of the most attractive growth assets in large cap biotech.” Citi also said Gilead's Quad drug and HIV franchise will boost the company's growth prospects going forward, but “the acquisition of Pharmasset

VRUS

will distinctly propel the company to potentially dominate the hepC landscape.”